Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Protocols MCP-841 and MCP-842 in ALL and NHL
NCT00018954Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Oct 1992
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of daunorubicin, vincristine, asparaginase escherichia coli, prednisone, methotrexate and 6 more in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and lymphoblastic lymphoma (LL) (3 arms), sponsored by National Institutes of Health. Primary endpoint: Safety and Effectiveness. Started Oct 1992; status: completed.
02
Drugs
daunorubicinvincristineasparaginase escherichia coliprednisonemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00018954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00018954.